NSC243928

02/25/2023 - "Further studies are required to understand the exact mechanism of NSC243928 action in inducing an anti-tumor immune response in vivo, which can be used to determine a molecular signature associated with NSC243928 efficacy. "
01/01/2023 - "These novel modified compounds will be employed in future in vitro and in vivo studies to understand the molecular mechanisms of NSC243928 mediated cancer cell death. "
02/25/2023 - "Furthermore, NSC243928 mounted an anti-tumor immune response by increasing immune cells such as patrolling monocytes, NKT cells, B1 cells, and decreasing PMN MDSCs in vivo. "
02/25/2023 - "Thus, we focused on studying whether NSC243928 may elicit an anti-tumor immune response in the in vivo mammary tumor models of 4T1 and E0771. "
02/25/2023 - "The molecular mechanism of NSC243928 as an anti-cancer agent in the treatment of tumor growth in the syngeneic mouse model has not been established. "

02/25/2023 - "NSC243928 induces cell death in triple-negative breast cancer cells in a LY6K-dependent manner. "
01/01/2023 - "Small molecule NSC243928 binds with LY6K, a potential target for the treatment of triple-negative breast cancer, and induces cancer cell death with an unclear mechanism. "

02/25/2023 - "NSC243928 may be a good target for future immuno-oncology drug development for breast cancer."